8.26

3.90% 0.31

After Hours: 8.25 -0.010 -0.12%

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is traded at $8.26, with a volume of 534.26K. It is up +3.90% in the last 24 hours and up +1.23% over the past month. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Previous Close:

$7.95

Open:

$8.08

24h Volume:

534.26K

Relative Volume:

0.41

Market Cap:

$466.73M

Revenue:

$217.11M

Net Income/Loss:

$-651.19M

P/E Ratio:

-11.63

EPS:

-0.71

Net Cash Flow:

$-387.26M

1W Performance:

+29.87%

1M Performance:

+1.23%

6M Performance:

-68.76%

1Y Performance:

-85.14%

1-Day Range:

$7.97

$8.35

1-Week Range:

$6.26

$8.35

52-Week Range:

$5.26

$75.20

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(877) 442-5362

Address

27 DRYDOCK AVENUE, BOSTON

Employee

1,218

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

DNA's Discussions on Twitter

Compare DNA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNA Ginkgo Bioworks Holdings Inc	8.26	466.73M	217.11M	-651.19M	-387.26M	-0.71
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

Nov 27, 2024

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock Holdings Cut by AH Capital Management L.L.C. - MarketBeat

Nov 27, 2024

Nov 21, 2024

Ginkgo Bioworks Advances Collaboration with Merck to Improve Bio - GuruFocus.com

Nov 21, 2024

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results - GuruFocus.com

Nov 21, 2024

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Pre - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Tao Capital Management LP - MarketBeat

Nov 20, 2024

Nov 19, 2024

US Bancorp DE Decreases Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat

Nov 19, 2024

Nov 18, 2024

How To Trade (DNA) - Stock Traders Daily

Nov 18, 2024

Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better (NYSE:DNA) - Seeking Alpha

Nov 18, 2024

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Short Interest Update - MarketBeat

Nov 18, 2024

Nov 16, 2024

GSA Capital Partners LLP Has $979,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St

Nov 15, 2024

Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 15, 2024

Nov 13, 2024

Ginkgo cancels move to new South Boston lab, exits Cambridge office - MassLive.com

Nov 13, 2024

Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call Transcript - MSN

Nov 13, 2024

Ginkgo Bioworks: Not Enough Progress (NYSE:DNA) - Seeking Alpha

Nov 13, 2024

Baillie Gifford & Co. Sells 131,067,285 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat

Nov 13, 2024

Nov 12, 2024

Ginkgo Bioworks Reports Q3 Growth and Strategic Deals - TipRanks

Nov 12, 2024

Ginkgo nixes move to South Boston lab, will exit Cambridge sites. Here's what it means - NBC Boston

Nov 12, 2024

Ginkgo nixes move to South Boston lab, will exit Cambridge sites - The Business Journals

Nov 12, 2024